These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16048486)

  • 1. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage.
    Wang N; Tsuruoka S; Yamamoto H; Enosawa S; Omasa T; Sata N; Matsumura T; Nagai H; Fujimura A
    Artif Organs; 2005 Aug; 29(8):681-4. PubMed ID: 16048486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model.
    Enosawa S; Miyashita T; Saito T; Omasa T; Matsumura T
    Cell Transplant; 2006; 15(10):873-80. PubMed ID: 17299991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system.
    Omasa T; Kim K; Hiramatsu S; Katakura Y; Kishimoto M; Enosawa S; Ohtake H
    Biotechnol Prog; 2005; 21(1):161-7. PubMed ID: 15903254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure.
    Enosawa S; Miyashita T; Fujita Y; Suzuki S; Amemiya H; Omasa T; Hiramatsu S; Suga K; Matsumura T
    Cell Transplant; 2001; 10(4-5):429-33. PubMed ID: 11549067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term culture of glutamine synthetase-transfected HepG2 cells in circulatory flow bioreactor for development of a bioartificial liver.
    Enosawa S; Miyashita T; Suzuki S; Li XK; Tsunoda M; Amemiya H; Yamanaka M; Hiramatsu S; Tanimura N; Omasa T; Suga K; Matsumura T
    Cell Transplant; 2000; 9(5):711-5. PubMed ID: 11144971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
    Araki N; Tsuruoka S; Wang N; Hasegawa G; Yanagihara H; Ando H; Omasa T; Enosawa S; Nagai H; Fujimura A
    Xenobiotica; 2008 Nov; 38(11):1355-64. PubMed ID: 18846481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a bioartificial liver with glutamine synthetase-transduced recombinant human hepatoblastoma cell line, HepG2.
    Miyashita T; Enosawa S; Suzuki S; Tamura A; Tanaka H; Amemiya H; Matsumura T; Omasa T; Suga K; Aoki T; Koyanagi Y
    Transplant Proc; 2000 Nov; 32(7):2355-8. PubMed ID: 11120198
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2.
    Enosawa S; Miyashita T; Tanaka H; Li X; Suzuki S; Amemiya H; Omasa T; Suga K; Matsumura T
    Transplant Proc; 2001; 33(1-2):1945-7. PubMed ID: 11267581
    [No Abstract]   [Full Text] [Related]  

  • 9. An attempt to add biological functions by genetic engineering in order to produce high-performance bioreactor cells for hybrid artificial liver: transfection of glutamine synthetase into Chinese hamster ovary (CHO) cell.
    Enosawa S; Suzuki S; Fujino M; Amemiya H; Omasa T; Urayama S; Tanimura N; Suga K
    Cell Transplant; 1997; 6(5):537-40. PubMed ID: 9331509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HepaRG cell line is suitable for bioartificial liver application.
    Hoekstra R; Nibourg GA; van der Hoeven TV; Ackermans MT; Hakvoort TB; van Gulik TM; Lamers WH; Elferink RP; Chamuleau RA
    Int J Biochem Cell Biol; 2011 Oct; 43(10):1483-9. PubMed ID: 21726661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase.
    Tang NH; Wang XQ; Li XJ; Chen YL
    Hepatobiliary Pancreat Dis Int; 2008 Dec; 7(6):621-7. PubMed ID: 19073408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application.
    Nibourg GA; Huisman MT; van der Hoeven TV; van Gulik TM; Chamuleau RA; Hoekstra R
    Liver Transpl; 2010 Sep; 16(9):1075-85. PubMed ID: 20818746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased hepatic functionality of the human hepatoma cell line HepaRG cultured in the AMC bioreactor.
    Nibourg GA; Hoekstra R; van der Hoeven TV; Ackermans MT; Hakvoort TB; van Gulik TM; Chamuleau RA
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1860-8. PubMed ID: 23770120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nonwoven fabric bioreactor immobilized with porcine hepatocytes for ex vivo xenogeneic perfusion treatment of liver failure in dogs.
    Naruse K; Sakai Y; Lei G; Sakamoto Y; Kobayashi T; Puliatti C; Aronica G; Morale W; Leone F; Qiang S; Ming SG; Ming S; Li Z; Chang SJ; Suzuki M; Makuuchi M
    Artif Organs; 2001 Apr; 25(4):273-80. PubMed ID: 11318756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver.
    Iwahori T; Matsuura T; Maehashi H; Sugo K; Saito M; Hosokawa M; Chiba K; Masaki T; Aizaki H; Ohkawa K; Suzuki T
    Hepatology; 2003 Mar; 37(3):665-73. PubMed ID: 12601364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial and bioartificial liver support: a review of perfusion treatment for hepatic failure patients.
    Naruse K; Tang W; Makuuch M
    World J Gastroenterol; 2007 Mar; 13(10):1516-21. PubMed ID: 17461442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamine-stimulated modification and degradation of glutamine synthetase in hepatoma tissue culture cells.
    Arad G; Freikopf A; Kulka RG
    Cell; 1976 May; 8(1):95-101. PubMed ID: 8212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of glutamine synthetase and carbamoylphosphate synthetase i in a bioartificial liver: markers for the development of zonation in vitro.
    Poyck PP; Hoekstra R; Vermeulen JL; van Wijk AC; Chamuleau RA; Hakvoort TB; van Gulik TM; Lamers WH
    Cells Tissues Organs; 2008; 188(3):259-69. PubMed ID: 18354250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.